期刊
TRENDS IN MOLECULAR MEDICINE
卷 20, 期 6, 页码 343-352出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2014.03.001
关键词
transcriptional repression; lymphomagenesis; gene enhancers; epigenetic regulation; BCL6; transcription factor targeted therapy
资金
- NCI NIH HHS [R01 CA143032, R01 CA104348] Funding Source: Medline
The B cell lymphoma 6 (BCL6) transcriptional repressor is a master regulator of the germinal center (GC) B cell program, required for their unique proliferative and stress tolerant phenotype. Most B cell lymphomas arise from GC B cells and are dependent on the continued or deregulated expression of BCL6 to maintain their survival. The actions of BCL6 in B cells involve formation of distinct chromatin modifying complexes that silence specific promoter and enhancer networks, respectively. The same biochemical mechanisms are maintained in malignant lymphoma cells. Targeted inhibition of these BCL6 functions has emerged as the basis for rational design of lymphoma therapies and combinatorial regimens. In this review, we summarize recent advances on BCL6 mechanisms of action and the deregulation of its target gene networks in lymphoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据